Business Wire

TII

14.12.2020 10:21:12 CET | Business Wire | Press release

Share
Technology Innovation Institute Appoints Global Cryptography Leaders as its Board of Advisors at Cryptography Research Centre

Technology Innovation Institute (TII), the applied research pillar of Advanced Technology Research Council (ATRC), today announced the formation of a board of advisors at Cryptography Research Centre (CRC). The new board of advisors comprises global experts in the field of cryptography.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201214005303/en/

The appointments follow a series of rapid announcements at Technology Innovation Institute since the first Advanced Technology Research Council board meeting in August 2020.

CRC is one of the initial seven dedicated centres at TII and it is also one of the few global centres bringing together theoretical and applied cryptographers in a research-oriented setting. The cryptographers collaborate on breakthrough research projects that lead to innovative outcomes in cryptography. Spanning fields from post quantum cryptography (PQC), lightweight cryptography, cryptanalysis, cryptographic protocols, hardware-based cryptography, confidential computing, amongst others, the distinguished board of advisors will guide efforts to develop breakthrough technologies for global impact, reinforcing the UAE’s position as a global hub for innovation and R&D.

The Board of Advisors includes: Prof Joan Daemen , Professor of Symmetric Cryptography at Radboud University in The Netherlands, who co-designed the Rijndael cipher that was selected as the Advanced Encryption Standard (AES) and is also one of the co-designers of the Keccak (SHA-3) cryptographic algorithm; Prof Lejla Batina , Professor of Hardware Cryptography at Radboud University, whose expertise is in applied cryptography and embedded systems security; Dr Guido Bertoni , CEO of Security Pattern, Italy, whose research areas include cryptographic algorithms, hardware-based cryptography, applied cryptography and embedded systems security. He is also a co-designer of the Keccak (SHA-3) cryptographic algorithm. Prof. Carlos Aguilar , Professor of ISAE SUPAERO in Toulouse University, France, a post quantum cryptographer and expert in secure cryptographic implementations and computational theory; Prof. Damien Stehlé , Professor in Computer Science at École Normale Supérieure de Lyon, France, whose focus areas are post quantum cryptography, computational theory and complex algebra; and Prof. Tim Güneysu, Professor of Security Engineering at Ruhr-University Bochum, Germany, who is an expert in secure hardware implementations, cloud cryptographic schemes and secure engineering.

CRC currently employs and collaborates with scientists in multiple crucial fields of cryptography. The experts are engaged in the full spectrum of fundamental and applied cryptography and cryptanalysis research.

Speaking on the board appointments, Dr Najwa Aaraj, Chief Researcher at CRC, said: “The success of any scientific and research-focused entity is led by its board of advisors as they support in setting the vision. By bringing together renowned experts, we are connecting global expertise in the field of cryptography.”

Dr Aaraj added: “Through the research undertaken at the Cryptography Research Centre, we are confident that Abu Dhabi and the UAE will pioneer breakthrough technologies that ensure even greater enhancements in high-priority cryptographic areas.”

TII is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The Institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem in Abu Dhabi and the UAE. The Institute reinforces Abu Dhabi and the UAE’s status as a global hub for innovation and contributes to the broader development of the knowledge-based economy.

To know more about Cryptography Research Centre (CRC):

tii.ae/cryptographytii.ae/cryptography

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye